glp-1 + nad EllieMD GLP-1 Agonists in Cardiovascular Diseases:
Description
O que dizem os estudos
otherwise even a large list-price gap will not force rapid switching in premium markets, while emerging markets tilt quickly to the lowest credible supplier
2018;11(6):e004886
All data are shown as meanstandard error of the mean
Background GLP-1 agonists continue to strain plan sponsor budgets due to soaring utilization rates
doi: 10.1016/S0140-6736(12)61267-7
